Keyi Liu

Title: **Innovator Profile: Keyi Liu - A Pioneer in Pulmonary Delivery Constructs**

Introduction

Keyi Liu is an accomplished inventor based in Mountain View, California, recognized for his innovative contributions to the field of drug delivery systems. With one patent to his name, Liu is making significant strides in enhancing therapeutic efficiency through novel delivery constructs.

Latest Patents

Keyi Liu holds a patent titled "Toxin-derived delivery constructs for pulmonary delivery." This patent encompasses isolated non-naturally occurring delivery constructs that consist of a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo. The technology is designed to facilitate the delivery of biologically active cargo via transcytosis transport across epithelial cells, while ensuring that the delivery construct does not contain a bacterial toxin-derived translocation domain or a catalytic (cytotoxic) domain. This innovation stands to revolutionize pulmonary drug delivery by enhancing the efficacy of therapeutic agents.

Career Highlights

Liu is employed at Applied Molecular Transport Inc., a company dedicated to advancing molecular transport technologies. His work focuses on developing strategies that leverage biologically active molecules for efficient delivery, showcasing his commitment to improving patient outcomes in various medical applications.

Collaborations

Throughout his career, Keyi Liu has collaborated with talented professionals, including Julia Dawn Mackay and Weijun Feng. These collaborations highlight the interdisciplinary approach that underpins Liu's innovative work, ensuring a comprehensive development of new technologies in the drug delivery arena.

Conclusion

Keyi Liu's pioneering work and patent in the development of toxin-derived delivery constructs for pulmonary use reflect his significant role in the field of pharmaceutical innovations. As he continues to collaborate and push the boundaries of traditional delivery methods at Applied Molecular Transport Inc., his contributions are sure to impact the future landscape of therapeutic delivery systems.